Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06813261 · ClinicalTrials.gov registry record · NA
GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women
A NA study of Metabolism and Postmenopause, sponsored by Buck Institute for Research on Aging.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06813261: Recruiting NA study of Metabolism and Postmenopause, sponsored by Buck Institute for Research on Aging.
NCT06813261 is a NA study of Metabolism and Postmenopause that is actively recruiting participants, run by Buck Institute for Research on Aging. The registered enrollment target is 30 participants, below the 13,264-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06813261, a NA study of Metabolism and Postmenopause, is actively recruiting participants, sponsored by Buck Institute for Research on Aging.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to assess the effectiveness of GLYLO, a dietary supplement, in postmenopausal women aged 45 to 65 who are overweight or obese and have elevated HbA1c levels. Specifically, the study seeks to evaluate whether GLYLO can reduce advanced glycation end products (AGEs) levels, which are harmful compounds formed when sugar attaches to proteins or fats in the body and can contribute to aging and disease. The primary outcome of the study is to determine if GLYLO reduces AGEs, enhances metabolic and hormonal health, and mitigates age-related functional decline. This study includes one screening visit and three testing visits over a 6-month period. After eligibility is confirmed, participants will be randomly assigned to one of two groups to take either GLYLO (two capsules daily) or a placebo at home for 24 weeks. Participants will provide blood samples at every visit. During the three testing visits, they will complete physical performance and cognitive function tests, provide both blood and urine samples, and fill out quality of life and 24-hour dietary intake questionnaires. The dietary intake questionnaires will be completed only twice i.e. at the baseline visit and again at the final 6-month visit.
Primary Outcome
MGO is a reactive dicarbonyl compound, measured by biochemical assays such as high-performance liquid chromatography (HPLC) or liquid chromatography-mass spectrometry (LC-MS) . The concentration of MGO is quantified to assess its role in the formation of advanced glycation end products (AGEs). Change is measured across the study
Conditions Studied
Interventions
- OTHER Placebo
- OTHER GLYLO
Study Locations (1)
California
- The Buck Institute for Research on Aging - Novato
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What NCT06813261 shows while recruiting
NCT06813261 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 13,264-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Metabolism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06813261 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06813261 about?
NCT06813261 is a clinical study titled "GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women". The aim of this study is to assess the effectiveness of GLYLO, a dietary supplement, in postmenopausal women aged 45 to 65 who are overweight or obese and have elevated HbA1c levels. Specifically, the study seeks to evaluate whether GLYLO can reduce advanced glycation end products (AGEs) levels, whi...
What is the current status of trial NCT06813261?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-04-01. Estimated completion is 2026-06-30.
What conditions does trial NCT06813261 study?
This clinical trial studies the following conditions: Metabolism, Postmenopause, Geroscience.
What interventions are being tested in trial NCT06813261?
The interventions under investigation include: Placebo (OTHER), GLYLO (OTHER).
Who is sponsoring clinical trial NCT06813261?
This trial is sponsored by Buck Institute for Research on Aging, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06813261 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06813261's enrollment target sits among peer trials
30 9th of 19 higher than 10 of 19 other Metabolism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metabolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells
RECRUITING · NA
-
Personalized Responses to Dietary Composition Trial 3
RECRUITING · NA
-
Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS
ACTIVE NOT RECRUITING · NA
-
Duration of Physical Inactivity and Postprandial Lipid Metabolism
COMPLETED · NA
-
Effects of a Caffeine- and Protein-Containing Coffee Beverage on Metabolism and Muscular Performance
COMPLETED · NA
-
Metabolic Effects of a Thermogenic Ready-to-drink Beverage
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI